Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
WEDNESDAY, Feb. 21, 2024 -- Patients with therapy-related myelodysplastic syndrome (t-MDS) and de novo MDS have comparable outcomes after haploidentical hematopoietic stem cell transplantation (haplo-HSCT), according to a study published online Feb....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Myelodysplastic Syndrome | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Study | Transplants